Kenneth Aldape
A5063290790- Glioma Diagnosis and Treatment
- Cancer Genomics and Diagnostics
- Meningioma and schwannoma management
- Epigenetics and DNA Methylation
- Brain Metastases and Treatment
- Radiomics and Machine Learning in Medical Imaging
- Cancer, Hypoxia, and Metabolism
- Neuroblastoma Research and Treatments
- MicroRNA in disease regulation
- Neurofibromatosis and Schwannoma Cases
- Chromatin Remodeling and Cancer
- Ferroptosis and cancer prognosis
- Cancer Immunotherapy and Biomarkers
- RNA modifications and cancer
- Cancer-related molecular mechanisms research
- Pituitary Gland Disorders and Treatments
- Lung Cancer Treatments and Mutations
- Childhood Cancer Survivors' Quality of Life
- Melanoma and MAPK Pathways
- Head and Neck Surgical Oncology
- Cancer Research and Treatments
- Sarcoma Diagnosis and Treatment
- Bioinformatics and Genomic Networks
- Single-cell and spatial transcriptomics
- Histone Deacetylase Inhibitors Research
National Cancer Institute
2013-2025
Center for Cancer Research
2011-2025
National Institutes of Health
2018-2025
Cancer Institute (WIA)
2024
National Cancer Institute
2021-2024
Hospital for Sick Children
2016-2024
Brigham and Women's Hospital
2024
National Institute of Health
2024
California University of Pennsylvania
2024
Rush University Medical Center
2024
Abstract Somatic mutations in cancer genomes are caused by multiple mutational processes, each of which generates a characteristic signature 1 . Here, as part the Pan-Cancer Analysis Whole Genomes (PCAWG) Consortium 2 International Cancer Genome (ICGC) and The Atlas (TCGA), we characterized signatures using 84,729,690 somatic from 4,645 whole-genome 19,184 exome sequences that encompass most types cancer. We identified 49 single-base-substitution, 11 doublet-base-substitution, 4...
Concurrent treatment with temozolomide and radiotherapy followed by maintenance is the standard of care for patients newly diagnosed glioblastoma. Bevacizumab, a humanized monoclonal antibody against vascular endothelial growth factor A, currently approved recurrent Whether addition bevacizumab would improve survival among glioblastoma not known.
Abstract Cancer is driven by genetic change, and the advent of massively parallel sequencing has enabled systematic documentation this variation at whole-genome scale 1–3 . Here we report integrative analysis 2,658 whole-cancer genomes their matching normal tissues across 38 tumour types from Pan-Cancer Analysis Whole Genomes (PCAWG) Consortium International Genome (ICGC) The Atlas (TCGA). We describe generation PCAWG resource, facilitated international data sharing using compute clouds. On...
Purpose Radiotherapy with concomitant and adjuvant temozolomide is the standard of care for newly diagnosed glioblastoma (GBM). O 6 -methylguanine-DNA methyltransferase (MGMT) methylation status may be an important determinant treatment response. Dose-dense (DD) results in prolonged depletion MGMT blood mononuclear cells possibly tumor. This trial tested whether DD improves overall survival (OS) or progression-free (PFS) patients GBM. Patients Methods phase III enrolled older than age 18...
Immunologic targeting of tumor-specific gene mutations may allow precise eradication neoplastic cells without toxicity. Epidermal growth factor receptor variant III (EGFRvIII) is a constitutively activated and immunogenic mutation not expressed in normal tissues but widely glioblastoma multiforme (GBM) other neoplasms.A phase II, multicenter trial was undertaken to assess the immunogenicity an EGFRvIII-targeted peptide vaccine estimate progression-free survival (PFS) overall (OS) vaccinated...
Chromothripsis is a mutational phenomenon characterized by massive, clustered genomic rearrangements that occurs in cancer and other diseases. Recent studies selected types have suggested chromothripsis may be more common than initially inferred from low-resolution copy-number data. Here, as part of the Pan-Cancer Analysis Whole Genomes (PCAWG) Consortium International Cancer Genome (ICGC) The Atlas (TCGA), we analyze patterns across 2,658 tumors 38 using whole-genome sequencing We find...
Purpose DNX-2401 (Delta-24-RGD; tasadenoturev) is a tumor-selective, replication-competent oncolytic adenovirus. Preclinical studies demonstrated antiglioma efficacy, but the effects and mechanisms of action have not been evaluated in patients. Methods A phase I, dose-escalation, biologic-end-point clinical trial was conducted 37 patients with recurrent malignant glioma. Patients received single intratumoral injection into biopsy-confirmed tumor to evaluate safety response across eight dose...